ANXA6 and neoplasm: Chemotherapy-induced tumour EVs promote proinflammatory endothelial cell activation, and chemokine (C–C motif) ligand 2 (CCL2) upregulation via a mechanism involving EV-associated annexin-A6 (ANXA6) translocation to the lung endothelium [34].